7. November 2021 – Walder Wyss advised 5AM Ventures, Roche Venture Fund and Sofinnova Partners as lead investors on the CHF 45m series A financing of GlycoEra AG.

GlycoEra’s innovative CustomGlycan platform unlocks the power of glycan-mediated biology to develop a pipeline of novel biologics for a broad range of indications.

Proceeds from the financing will be used to support the growth of the company and to demonstrate the breadth and value of its CustomGlycan Platform technology in developing assets that can unlock unique biological activities for therapeutic targets in several disease indications.

The Walder Wyss team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and included Michelle Bruni (Senior Associate, Corporate/M&A and Tax), Karina Tschon (Associate, Corporate/M&A and Venture Capital) and Lena Götzinger (Associate, IP/IT and Licensing).